Clinical Trial

Psilocybin Whole Mushroom for the Treatment of Obsessive-compulsive Disorder.

Study acronym: Mushroom-OCD
Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The study tries to improve our treatments for people who have obsessive-compulsive disorder (OCD) by testing psilocybin, a mind altering drug that changes activity in brain areas involved in OCD. 30 patients with moderate or more severe OCD who are not taking mind altering medications or street drugs will participate in a 12 week study. Participants will be assigned (by luck of the draw) to take a low, medium, or high dose whole psilocybin mushroom contained in three chocolate pieces, prepared for this study by the Scottsdale Research Institute.
Protocol Amendment History 2 changes
notable Primary completion pushed: 2028-01 -> 2028-12-31 2026-07-24
minor Completion pushed: 2029-01 -> 2029-01-31 2026-07-24
Trial Details
NCT Number NCT07347405
Lead Sponsor Francisco A Moreno
Collaborators: Arizona Biomedical Research Commission (ABRC)
Conditions Obsessive-Compulsive Disorder
Enrollment 30 participants
Start Date 2026-05-18
Primary Completion 2028-12-31 (estimated)
Study Completion 2029-01-31 (estimated)
Updated on ClinicalTrials.gov 2026-07-23